BiotechTube
Lateral Pharma

Lateral Pharma

Melbourne, Australia· Est.

An Australian biotech developing first-in-class LanCL-targeting therapies for neuropathic pain, neurodegeneration, and healthy ageing.

lateral-pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

An Australian biotech developing first-in-class LanCL-targeting therapies for neuropathic pain, neurodegeneration, and healthy ageing.

OncologyImmunologyNeurologyPainInfectious Disease

Technology Platform

Stressed Cell Protective (SCP) platform developing peptide and small molecule drugs that activate LanC-like (LanCL) proteins, a novel endogenous pathway that protects cells from stress, inflammation, and damage.

Opportunities

The LanCL pathway offers a first-in-class, disease-modifying approach in neuropathic pain (non-opioid) and neurodegeneration, with potential expansion into large markets like healthy ageing (healthspan) and host-directed therapies for respiratory infections.

Risk Factors

Clinical risk: LAT9997 must demonstrate efficacy in larger trials; platform risk: novel LanCL target is unproven in late-stage development; financial risk: as a private, pre-revenue company, dependent on raising capital in a competitive funding environment.

Competitive Landscape

In neuropathic pain, competes with neuromodulators, antidepressants, and novel mechanisms; differentiation is non-opioid, potentially curative LanCL targeting. In Alzheimer's, enters a field dominated by amyloid/tau-targeting biologics; differentiation is neuroprotection via stress pathway modulation.

More companies in Australia →